Suppliers and packagers for DOXIL (LIPOSOMAL)

DOXIL (LIPOSOMAL)

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Baxter Hlthcare Corp	DOXIL (LIPOSOMAL)	doxorubicin hydrochloride	INJECTABLE, LIPOSOMAL;INJECTION	050718	NDA	Baxter Healthcare Company	0338-0063-01	1 VIAL, SINGLE-USE in 1 CARTON (0338-0063-01) / 10 mL in 1 VIAL, SINGLE-USE	2019-08-13
Baxter Hlthcare Corp	DOXIL (LIPOSOMAL)	doxorubicin hydrochloride	INJECTABLE, LIPOSOMAL;INJECTION	050718	NDA	Baxter Healthcare Company	0338-0067-01	1 VIAL, SINGLE-USE in 1 CARTON (0338-0067-01) / 25 mL in 1 VIAL, SINGLE-USE	2019-08-13
Baxter Hlthcare Corp	DOXIL (LIPOSOMAL)	doxorubicin hydrochloride	INJECTABLE, LIPOSOMAL;INJECTION	050718	NDA AUTHORIZED GENERIC	Baxter Healthcare Company	0338-0080-01	1 VIAL, SINGLE-USE in 1 CARTON (0338-0080-01) / 10 mL in 1 VIAL, SINGLE-USE	2019-08-15

Suppliers and packagers for DOXIL (LIPOSOMAL)

Last updated: May 30, 2026

DOXIL (liposomal doxorubicin) suppliers and contract manufacturing: Who makes the drug product, active ingredient, and key raw materials?

Suppliers for DOXIL split into (1) active pharmaceutical ingredient (API) and key starting materials for liposomal doxorubicin, (2) lipid and auxiliary excipients used to form PEGylated liposomes, and (3) contract manufacturing organizations (CMOs) and pharmaceutical manufacturers that fill and finish or commercial-pack supply of DOXIL. The commercial product is linked to the branded product supply chain controlled by the marketing authorization holder and its manufacturing/QA network.

Who supplies lipids, PEGylated components, and excipients used to manufacture DOXIL?

DOXIL is a PEGylated liposomal formulation of doxorubicin (liposomal doxorubicin hydrochloride). Commercial manufacturing uses a defined lipid system and excipients consistent with PEGylated liposome platforms, typically including:

• Phospholipid component(s) (eg, hydrogenated soy phosphatidylcholine-like lipids or equivalent hydrogenated phosphatidylcholine grades)
• Cholesterol (or equivalent sterol component)
• PEG-lipid (eg, DSPE-PEG or equivalent PEGylated phospholipid)
• Cryoprotectants / buffers consistent with liposome stabilization and doxorubicin loading/retention (exact composition is formulation-specific and controlled by the manufacturing process)

Supplier landscape in this category is generally concentrated among global specialty lipid and excipient suppliers that can provide GMP-grade materials, including:

• Specialty lipid manufacturers supplying PEG-lipids and hydrogenated phospholipids
• Excipients suppliers supplying buffer components and stabilizers compatible with sterile liposome drug products
• GMP analytical services for lipid grade confirmation (often integrated with CMO QA systems rather than sourced as standalone vendors)

Who are the contract manufacturing suppliers for DOXIL drug product (fill-finish and sterile liposome manufacturing)?

DOXIL is manufactured by CMO and/or internal manufacturing sites under controlled technology transfer, sterile processing, and validated lyophilization or aqueous fill-finish depending on product configuration. In practice, DOXIL drug product supply is managed by:

• A primary commercial manufacturer for bulk liposome production and sterile fill
• One or more secondary or supplemental manufacturing sites for scale-up, lifecycle tech transfers, or supply continuity

The “supplier” question for DOXIL is therefore usually answered at two levels:

1. Regulatory manufacturer(s) listed on the FDA label and/or drug application manufacturing section (site of manufacture, sterile manufacturing, and packaging)
2. Chain-of-custody suppliers for lipids and excipients under audited GMP quality systems

What patents and platform IP affect DOXIL manufacturing and supplier qualification?

DOXIL’s supplier base is shaped by platform IP and specific formulation/process protections. Even when generic liposomal doxorubicin is marketed, sourcing the exact manufacturing-ready liposome technology typically requires licensing or development work under the non-infringing space.

Key IP buckets affecting suppliers:

• Liposomal doxorubicin formulation IP: lipid composition, PEGylation strategy, doxorubicin encapsulation and retention
• Manufacturing method IP: mixing/hydration parameters, remote loading or encapsulation strategy, size distribution control
• Stability and shelf-life IP: drug product storage behavior, particle size drift limits, and stabilizer systems

Supplier qualification typically requires either (a) operating under authorized manufacturing rights or (b) a non-infringing independent process development.

Which companies supply the doxorubicin API and doxorubicin hydrochloride starting material used for DOXIL?

DOXIL uses doxorubicin in a liposomal encapsulation system. API supply is commonly provided by:

• Oncology-focused API manufacturers with anthracycline production capability
• Sterility-exempt chemical API providers with validated crystal form and impurity profiles to match liposome loading requirements

In an audited GMP supply chain, API vendors are selected based on:

• impurity profiles and acceptance criteria
• particle size and solid-state properties (impacting encapsulation reproducibility)
• traceability for regulatory submissions and batch release

How does the DOXIL supplier chain differ from generic or biosimilar liposomal doxorubicin suppliers?

Generic DOXIL competitors (and later entrants) typically diverge by:

• Different lipid recipes or PEG-lipid choices
• Different manufacturing process controls for size distribution, encapsulation efficiency, and doxorubicin retention
• Different fill-finish sites and different analytical package owners

That changes which suppliers can qualify, since lipid grades and process-critical excipients must match the platform used by the generic sponsor and its chosen CMO.

What is the Orange Book status and what does it imply for DOXIL-related supplier availability?

The branded DOXIL product is listed in the FDA Orange Book for patents covering:

• the drug product (composition and/or formulation)
• use and method-of-use claims (where applicable)
• manufacturing or process claims (where listed)

When relevant exclusivities and patents have run, the supplier ecosystem can widen due to increased CMO availability for liposome drug product manufacturing and more API and lipid sourcing options under competitive tendering. For ongoing exclusivity/patent protection periods, supplier availability is more constrained by authorized manufacturing rights and technology access.

What generic entry risks exist for DOXIL and how do they impact supplier choices?

The main generic entry risks for a branded liposomal oncology product include:

• difficult-to-replicate liposome critical quality attributes (CQAs) that drive similarity
• regulatory risk around particle size distribution, encapsulation efficiency, and release profile
• process validation risk that pushes reliance to CMO networks with demonstrated liposome regulatory track records

These risks lead companies to select suppliers (lipid vendors, API vendors, and CMOs) with strong audit histories and proven capability for liposomal sterile drug products.

Which CMOs and manufacturers are most likely to be involved in DOXIL supply continuity?

For DOXIL specifically, the supplier set is best determined by:

• the label “Manufactured for” / “Manufactured by” information
• listing of manufacturing and packaging sites in regulatory documentation
• inspectional history and typical liposome CMO roles (sterile manufacturing, QA release, and stability testing)

In practice, only a subset of global CMOs has the validated equipment, sterile process capabilities, liposome formulation control infrastructure, and regulatory documentation maturity required for a complex oncology liposome product.

How do DOXIL formulation and manufacturing requirements constrain lipid and PEG-lipid suppliers?

Lipid and PEG-lipid suppliers must meet tight constraints because they affect:

• liposome size distribution and stability
• PEG chain density and colloidal stability
• doxorubicin encapsulation efficiency and retention
• batch-to-batch reproducibility, a major factor in both regulatory release and comparability for any lifecycle change

As a result, suppliers that cannot supply consistent hydrogenation profile, PEG-lipid purity, and GMP documentation tend to be excluded.

Commercial question: Who controls DOXIL supply through manufacturing authorizations and quality release?

Commercial control typically concentrates in:

• the marketing authorization holder (responsible for regulatory compliance and release specifications)
• the primary manufacturing site(s) named for commercial supply
• the QA release unit that signs batch disposition

Downstream, contract packaging and distribution can be performed by logistics and packaging partners, but release authority remains with the regulated manufacturer(s).

Key DOXIL supply chain map (what to source and who typically owns each link)

Supply chain link	What it provides	Typical supplier type	What to validate for procurement
Lipid system	Phospholipids, cholesterol, PEG-lipids	Specialty lipid suppliers	GMP CoA, grade consistency, PEG-lipid purity and specs
Buffering and stabilization components	Formulation excipients	Excipients manufacturers	compatibility with liposome stability and sterile processing
API	Doxorubicin hydrochloride / doxorubicin	Oncology API manufacturers	impurity profile, solid-state attributes, batch traceability
Liposome drug product manufacturing	Bulk liposome formation and drug loading	Liposome-capable CMOs / internal manufacturing	particle size control, encapsulation efficiency, retention specs
Sterile fill-finish and packaging	Vials, labeling, secondary packaging	sterile fill-finish sites	sterile processing validation, traceability and packaging QA

Key Takeaways

• DOXIL supplier coverage breaks into lipid/PEG-lipid and excipient supply, doxorubicin API supply, and specialized sterile liposomal drug product manufacturing plus fill-finish.
• The practical “who supplies DOXIL” answer is driven by FDA label manufacturing authorizations and by which CMOs have the validated sterile liposome process capability.
• Lipid and PEG-lipid suppliers are constrained by tight critical quality attribute impact on particle size, PEG density, and doxorubicin retention.
• Supplier decisions for DOXIL-linked programs must align with the controlled manufacturing process and IP landscape shaping technology access and process similarity.

FAQs

1. What excipients and PEG-lipids are used in PEGylated liposomal doxorubicin formulations like DOXIL?
2. How do particle size and encapsulation efficiency specifications affect selection of liposome CMOs for DOXIL manufacturing?
3. What qualification requirements apply to doxorubicin API suppliers for liposomal products compared with conventional doxorubicin?
4. Do DOXIL generics and follow-on liposomal doxorubicin products use the same lipid suppliers as the originator?
5. Which parts of the DOXIL supply chain are most constrained during supply disruptions: API, lipids, or sterile fill-finish capacity?

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
2. FDA. Drug Label Information for DOXIL (pegylated liposomal doxorubicin).